Compound Ac13, also termed AURKA against 1, acts as an inhibitor of the Aurora kinase (AURKA) with an IC50 of less than 0.5 nM, targeting the acetylation of endogenous lysine (K162) and exhibiting anti-tumor cell proliferation activity. The kinase activity of AURKA, acetylated at K162 and induced by AURKA against 1, is reversibly restored in HCT116 cells transfected with SIRT3.

Ac13 在不同浓度下对肿瘤细胞具有明显抑制效果。在0-10 μM浓度、作用3小时的条件下，Ac13在K562、HL-60 和 CCRF-CEM细胞系中展示了剂量依赖性的抗增殖活性，其GI 50 分别为588、86 和 6.6 nM。该化合物通过抑制AURKA的自磷酸化，进而降低细胞活性。此外，当Ac13的浓度为10 μM、作用时间为1小时时，其能够诱导HCT116细胞（表达SIRT3）中AURKA的K162位点的乙酰化，该乙酰化过程是可逆的。